ReviewACS central science2025
Brightening New Horizons: Luminescent Transition Metal Complexes in Optical Imaging and Theranostic Applications.
Review in ACS central science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Controlled Dimerization of Rhodium(I) Isocyanides Enables Photophysical Properties Beyond Mononuclear Complexes.JACS Au · 2026Article
- Ultrasound-activatable transition metal complexes to potentiate sonodynamic therapy.Chemical science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small-molecule fluorescent probes have revolutionized fluorescence imaging in both biological research and clinical applications, allowing the exploration of intricate cellular processes and aiding disease diagnosis and treatment. Advances in the designs of molecular probes have led to the development of fluorescent theranostics that combine therapeutic and diagnostic modalities in a single platform. These dual-functional agents enable simultaneous disease diagnosis, treatment, and monitoring, representing an innovative approach to precision medicine. Luminescent transition metal complexes have emerged as promising alternatives to traditional organic fluorophores for optical imaging and theranostic applications, and they offer distinctive advantages such as high photostability, long emission lifetimes, and efficient generation of reactive oxygen species. In this Outlook, we highlight emerging trends in the designs and applications of luminescent transition metal complexes as optical imaging and theranostic agents, leveraging their unique photophysical and photochemical properties. We also discuss current challenges to the clinical applications of these complexes and outline potential directions to inspire the development of next-generation theranostics for advancing disease management and improving patient care.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.